Oncology & Cancer

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Oncology & Cancer

New pretargeted radioimmunotherapy for colorectal cancer

Investigators at SNM's 58th Annual Meeting are presenting results from a phase 1 clinical trial for a cancer therapy that has the potential to kill colorectal tumors with less destruction of healthy tissue. Further research ...

page 8 from 19